KRKirill Pavlovich Raevskii

Kirill Pavlovich Raevskii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kirill Pavlovich Raevskii has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of cardiovascular drugs on erectile function: Literature review

    by K. P. Raevskiy, O. Yu. Nesterova, A. A. Kamalov, Ya. A. Orlova, К. П. Раевский, О. Ю. Нестерова, A. А. Камалов, Я. А. Орлова

    Erectile dysfunction (ED) is a common problem among the male population over 40 years old. Arterial hypertension, dyslipidemia and other cardiovascular diseases (CVDs), as well as some of the medications which are used to treat CVDs can affect erectile function (EF). This article discusses current data about cardiovascular drugs effect on EF and analyzes scientific literature from the following scientific databases: PubMed, ScienceDirect, and eLIBRARY.RU. Angiotensin II receptor blockers have a positive effect on EF. ED, as one of the possible side effects, can be observed during treatment by most beta-blockers (with the exception of nebivolol), diuretics, and non-selective mineralocorticoid receptor antagonists. There is no convincing evidence of a negative effect of angiotensin-converting enzyme inhibitors, calcium channel blockers, selective mineralocorticoid receptor antagonists, and metoprolol on EF. The data of the effect of statin therapy on EF is contradictory. There is a limited number of studies about interaction between angiotensin receptors, neprilysin inhibitors and EF. In many studies subjective methods of EF assessment are used. CVDs and ED have common risk factors and pathogenic mechanisms. Large-scale biobank studies using Mendelian randomization show that ED is more strongly associated with the presence of CVDs rather than with the medications. To clarify CVD drugs effects on EF it is necessary to conduct studies with objective assessment of EF using nighttime penile tumescence monitoring. Knowledge of the characteristics of CVD drugs allows doctors to provide patient with an individualized therapy without adverse events, and ensures a high level of patient adherence to treatment.

  • Open Access

    Current capacities for neuroimaging in epilepsy. A review

    by Svetlana M. Karelova, Milena Y. Kopchak, Anastasia L. Portniagina, Olga N. Fefelova, Anna I. Yakovleva, Alina E. Isabekova, Kirill P. Raevskii, Vladimir V. Otochkin

    The article is devoted to modern neuroimaging methods in the diagnosis and treatment of epilepsy, including magnetic resonance imaging, positron emission computed tomography, single-photon emission computed tomography and proton magnetic resonance spectroscopy. Their role in identifying epileptogenic foci, monitoring of activity, and planning of surgical treatment is discussed. Current research from scientific databases such as PubMed, ScienceDirect, Neurology Journal, MDPI, and Wiley Online Library is analyzed. Currently, there are two directions of neuroimaging development. On the one hand, scientists are striving to increase the strength of the magnetic field using ultra high-field magnetic resonance imaging 7T, on the other hand, biochemical changes in the ictal, postictal and interictal periods are continuously being studied. Based on these data, a search is underway for biochemical markers that will improve the accuracy of proton magnetic resonance spectroscopy, as well as develop new radiopharmaceuticals. The integrated use of radiation methods makes it possible to increase the accuracy of diagnostic search and achieve more successful surgical outcomes in patients with refractory epilepsy. The article may be of interest to psychiatrists, neurologists, specialists in radiation and functional diagnostics.


  • Hypertension and sex hormone levels in young and middle-aged men

    by Iana A. Orlova, Egor D. Sorokin, Zukhra Sh. Pavlova, Alina G. Plisyuk, Kirill P. Raevskii, Armais A. Kamalov

    Hypertension is a major cardiovascular condition and exhibits significant sexual dimorphism. The prevalence of hypertension in the general population could be associated with the state of sex hormone system to a large degree. Currently the data obtained on the relationship between sex hormones and blood pressure levels are insufficient. Research aim To study the relationship between hypertension and sex hormone levels in young and middle-aged men in a retrospective cohort study setting. Materials and methods A retrospective observational clinical trial was conducted. 698 medical records of male patients aged 18 to 59 years were analyzed. 508 patients with an average age of 41.1±9.4 years, obesity prevalence of 48.2%, and hypertension prevalence of 52% were selected. Blood pressure levels, anthropometric data, levels of sex hormones, lipid panel and insulin resistance indicators were analyzed. Results: In our study group, obesity and its abdominal form were more common among patients with hypertension. A decrease in the testosterone level (12.1 nmol/l) was significantly more common among patients with hypertension (64.91% versus 41.98%, p=0.001). Differences in the prevalence of hyperestrogenism (estradiol level above 41.2 pg/ml) did not reach statistically significant values ​​(29.43% versus 22.22%, p=0.064). When dividing the study sample by E2 tertiles, the groups significantly differed from each other in the prevalence of hypertension (p=0.028). According to the results of multivariate logistic analysis, sex hormones made a significant contribution to the model of the presence of hypertension. High levels of estradiol were associated with a higher probability of hypertension, while lower levels reduced the probability of hypertension. The relationship between T and hypertension was inverse: the higher the level of this hormone, the lower the probability of hypertension in young and middle-aged men. Conclusions: Our study shows the presence of an independent relationship between the level of testosterone and estradiol and the presence of hypertension in young and middle-aged men.

  • Open Access

    Association between cardiovascular drugs and erectile function quality assessed by nocturnal penile tumescence monitoring

    by Armais A. Kamalov, Yana A. Orlova, Michail E. Chaliy, Olga Yu. Nesterova, Andrew A. Strigunov, Kirill P. Raevskii, Anastasia D. Tereshina, Чалый Михаил Евгеньевич

    BACKGROUND: In patients with cardiovascular risk factors, erectile dysfunction is an early marker of subclinical generalized vascular damage. Furthermore, cardiovascular drugs may impair erection quality. AIM: The work aimed to determine the relationship between cardiovascular drugs and erectile function quality assessed by nocturnal penile tumescence monitoring. METHODS: This retrospective study included 100 male patients who consecutively presented with complaints of erectile dysfunction between 2020 and 2022. All participants underwent nocturnal penile tumescence monitoring, and the results were evaluated using the criteria developed by Academician Kamalov and Professor Chaliy. RESULTS: Patients with moderate/severe erectile dysfunction were nearly five times more likely to take spironolactone (18.9% vs. 4.8%, p = 0.036) and 2.5 times more likely to use diuretics (24.3% vs. 9.5%, p = 0.087) than those with no/mild erectile dysfunction. The total number of cardiovascular drugs used by patients with moderate/severe erectile dysfunction was twice as high as in those with no/mild erectile dysfunction, according to nocturnal penile tumescence findings. The frequency of β-blocker, statin, metformin, and renin–angiotensin–aldosterone system inhibitor use was comparable between the groups. Spironolactone and diuretics were associated with a 4.7-fold (odds ratio [OR]: 4.667; 95% confidence interval [CI]: 1.126–19.340; p = 0.034) and 3.1-fold (OR: 3.054; 95% CI: 0.989–9.431; p = 0.052) increased risk of moderate/severe erectile dysfunction, respectively. Moreover, the number of cardiovascular drugs taken increased the risk of moderate/severe erectile dysfunction based on nocturnal penile tumescence monitoring. Each additional drug increased the odds of moderate/severe erectile dysfunction by 1.3 times (OR: 1.304; 95% CI: 1.003–1.694; p = 0.047), primarily due to a reduction in nocturnal penile tumescence duration. CONCLUSION: Spironolactone, known for its antiandrogenic effects, increased the odds of moderate/severe erectile dysfunction by 4.7 times based on nocturnal penile tumescence monitoring. Diuretic therapy was associated with more pronounced erectile dysfunction, whereas other cardiometabolic drugs did not affect erection quality. According to nocturnal penile tumescence monitoring, using more cardiovascular drugs was a significant risk factor for moderate/severe erectile dysfunction. This likely reflects more severe cardiovascular disease, which contributes to the onset and progression of erectile dysfunction.

  • Open Access

    The relationship between the composition of the gut microbiota and respiratory infection COVID-19: A review

    by Elizaveta A. Kapustina, Danila V. Sokolov, Daniil A. Zharenkov, Ulyana A. Shushunina, Kirill P. Raevskii

    The article presents a review of modern foreign and Russian literature, summarizing the data of the influence of intestinal microbiota on COVID-19 course and the components and quantities of microbiota changing due to coronavirus infection. The results of many studies indicate the immune response against new coronavirus infection modulation, including stimulation of the synthesis of cytokines, immunoglobulins, regulation of the expression of viral target receptors and maintaining the tone of the immune system. This principle determines the severity of the disease depending on the state of the microbiota. On the other hand, in addition to respiratory symptoms, gastrointestinal disorders are observed with SARS-CoV-2 infection, which indicates the tropism of the virus to intestinal cells and the effect on the microbiota. The described two-way relationship is called ”gut-lung axis” and opens up opportunities for stimulating the immune response against SARS-CoV-2 and improving the prognosis.


  • Open Access

    Cystic Fibrosis: New Trends in Therapy Methods

    by P. A. Suchkova, S. A. Panova, O. Ya. Lisenko, K. P. Raevskij

    This review provides information on recent advancements in the treatment of cystic fi brosis and presents interim results from ongoing clinical trials. Various scientifi c databases, including Scopus, Web of Science, and EMBASE, were utilized during the preparation of this review.The results of studies on new drugs such as acebilustat, LAU-7b, JBT-101 designed for anti-infl ammatory therapy of this disease are also presented.The review describes various approaches to cystic fi brosis therapy — substance ABO401, SP-101. It includes clinical trial results for the adeno-associated vector 4D-710, liposomal nanoparticles, including the drugs MRT5005, RCT2100, the corrector galicaftor, as well as the drugs lumacaftor+ivacaftor, tezacaftor+ivacaftor, tezacaftor+ivacaftor+elexacaftor и tezacaftor+vanzacaftor+deutivacaftor.Special attention is given to transgene delivery using vectors with a detailed discussion of the advantages and disadvantages of this method. The main modern genome editing techniques, their capabilities, advantages and disadvantages are also described.The results of the study on the oligosaccharide structures, which reduces sputum viscosity in patients with cystic fi brosis, are presented. This reduction in viscosity enhances the effectiveness of the antibiotic aztreonam, which is active against the Burkholderia cepacia complex — a group of pathogens, which is often responsible for infl ammation in cystic fi brosis patients.The role of targeted therapy as a factor capable of signifi cantly reducing disease severity was highlighted. Targeted therapy drugs can partially restore the function of the abnormal protein in cystic fi brosis patients, thereby reducing symptom severity and signifi cantly improving the patient’s quality of life. The necessity of further development in this fi eld was emphasized.


  • Open Access

    A randomized controlled trial of statin therapy effect on androgen status and erectile function in men with high and very high cardiovascular risk (TRISTAN): rationale and study protocol

    by K. P. Raevskii, O. Yu. Nesterova, A. A. Strigunov, M. E. Chaliy, A. V. Kadrev, A. G. Plisyuk, A. A. Kamalov, Ya. A. Orlova

    Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk. Additionally, to assess the association between sex hormone levels, erectile function parameters, and traditional cardiovascular risk factors, arterial stiffness, and endothelial function in this patient category.Material and methods. It is planned to conduct a prospective randomized controlled trial, including 150 male patients aged 40-65 years, undergoing routine preventive examinations in the clinic of Moscow State University, having a high and very high risk of CVD and meeting the inclusion criteria. Group 1 (n=75) will receive pitavastatin at a starting dose of 1 mg/day. Group 2 (n=75) will receive rosuvastatin 20 mg/day. After 3 months, the biochemical parameters will be monitored, and dose titration of pitavastatin to 2-4 mg/day and/or rosuvastatin to 40 mg/day will be performed if necessary. Patient recruitment to the study will occur over 9 months at a single research center. Patients will be monitored with an objective assessment of erectile function parameters, blood analysis (including androgen status), central arteries stiffness, and endothelial function for 6 months from the moment of activation. Follow-up visits are scheduled at 1, 3 and 6 months.Results. The expected result of testing the research hypothesis is that statin therapy will not have a negative effect on androgen status and erectile function in men. Intensive statin therapy will have a greater positive effect on endothelial function, which may lead to an improvement in men’s erectile function.Conclusion. The study was planned under the assumption that statin therapy would not have a negative effect on androgen status and erectile function in men aged 40-65 years. It is also suggested that the positive effect of statins on endothelial function and vascular stiffness may lead to an improvement in erectile function among men with high and very high cardiovascular risk. If the hypothesis is confirmed, the results obtained will help improve statin treatment adherence in male patients and, as a result, increase the effectiveness of prevention of cardiovascular events.

  • Association between metabolic syndrome and osteoporosis in older adults: a review

    by Yana Olegovna Shelaeva, Elizaveta Olegovna Golubeva, Valentina Viktorovna Gritsenko, Sofya Andreevna Ovchinnikova, Veronika Olegovna Popkova, Anita N. Baranova, Kirill P. Raevskii

    Metabolic syndrome is a condition characterized by abdominal obesity, hypertension, insulin resistance, and disorders of carbohydrate and lipid metabolism. The highest prevalence of metabolic syndrome is observed among older adults. A decline in estrogen levels in postmenopausal women increases the risk of both metabolic syndrome and osteoporosis, especially if associated with vitamin D deficiency. Osteoporosis is one of the most important medical and social problems. Its pathogenesis may be related not only to hormonal changes but also to alterations in the composition of the gut microbiota. Gut microbial dysbiosis in metabolic syndrome is exacerbated by chronic inflammation, inappropriate pharmacotherapy, and comorbid conditions (such as consequences of gastrectomy, bariatric surgery, malabsorption syndrome, atrophic gastritis, and other diseases). These factors can alter microbial metabolites and mineral metabolism, thereby contributing to decreased bone mineral density. Thus, modulation of the microbiota and its metabolites in patients with metabolic syndrome may be considered a promising approach for the prevention and treatment of osteoporosis in older adults.

  • Targeted therapy in older adults with Alzheimer disease: a review

    by Polina A. Bulina, Polina A. Popova, Lyubov S. Dyatchina, Mariia M. Goliatina, Anastasia P. Zaitseva, Anastasiia A. Abramenko, Kirill P. Raevskii, Дятчина Любовь Сергеевна, Голятина Мария Михайловна, Зайцева Анастасия Павловна

    One of the most pressing issues today is the somatic and mental health of older adults due to increasing life expectancy and expanding diagnostic capabilities for various diseases. Alzheimer disease has a significant impact on the quality of life of patients and their families and results in substantial economic and social consequences for society. Patients with Alzheimer disease require continuous care and support, which demands considerable resources from health care and social service systems. Moreover, Alzheimer disease leads to reduced work productivity and increased health care expenditures. This review analyzes foreign and Russian articles published in the past 5 years in Scopus, PubMed Central, the Cochrane Library, and BMJ Case Reports regarding targeted therapy for Alzheimer disease, one of the most common neurodegenerative disorders that reduce quality of life. This review considers the main principles of targeted therapy used in older adults with Alzheimer disease are considered, along with its advantages, limitations, and future perspectives for this therapeutic approach.

  • Open Access

    Leptomeningeal melanomatosis: a case report

    by Diana Maratovna Fedorova, Alina Aleksandrovna Sokolova, Olga Andreevna Popova, Arina Eduardovna Yarkina, Anna Vital’evna Svintsova, Tatiana Viktorovna Kochetova, Kirill Pavlovich Raevskii, Ivan Vladimirovich Sheladev

    INTRODUCTION: Leptomeningeal melanomatosis is a rare neoplasm of the central nervous system that develops as a result of non-metastatic invasion by malignant melanocytic cells. The disease poses significant diagnostic challenges due to a wide range of clinical manifestations, lack of specific laboratory markers, and absence of definitive neuroimaging findings. Particular attention should be given to differentiating leptomeningeal melanomatosis from other central nervous system disorders, infectious and neoplastic diseases of different origin, and metastases, given the similarities in clinical presentation and pathomorphological features. CASE DESCRIPTION: A 20-year-old patient was diagnosed with leptomeningeal melanomatosis. Despite the absence of detectable melanoma in biopsy (surgical) specimens during antemortem pathological examination, the scientific data indicates that this does not preclude an aggressive clinical course following symptom onset. The report presents the patient’s clinical history and disease progression over one year, culminating in a fatal outcome. CONCLUSION: This case illustrates the diagnostic and therapeutic difficulties associated with rare central nervous system disorders, particularly when the diagnosis remains unclear over a long period. The scarcity of reliable data on leptomeningeal melanomatosis, the rapid disease progression, and its high mortality make timely diagnosis extremely challenging.